Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mahnaz Shekari

Showing results (41-50 of 59) with videos related to

Pageof 6
Sort By:
EJNMMI Research|March 1, 2023
APOE-ε4 modulates the association between regional amyloid deposition and cognitive performance in cognitively unimpaired middle-aged individualsAnna Brugulat-Serrat, Gonzalo Sánchez-Benavides, Raffaele Cacciaglia, et al.
Nature Medicine|September 13, 2022
Publisher Correction: Plasma p-tau231 and p-tau217 as state markers of amyloid-β pathology in preclinical Alzheimer's diseaseMarta Milà-Alomà, Nicholas J Ashton, Mahnaz Shekari, et al.
Nature Medicine|August 11, 2022
Plasma p-tau231 and p-tau217 as state markers of amyloid-β pathology in preclinical Alzheimer's diseaseMarta Milà-Alomà, Nicholas J Ashton, Mahnaz Shekari, et al.
EMBO Molecular Medicine|November 10, 2020
Novel tau biomarkers phosphorylated at T181, T217 or T231 rise in the initial stages of the preclinical Alzheimer's continuum when only subtle changes in Aβ pathology are detectedMarc Suárez-Calvet, Thomas K Karikari, Nicholas J Ashton, et al.
Brain Communications|July 5, 2022
Regional associations of white matter hyperintensities and early cortical amyloid pathologyLuigi Lorenzini, Loes T Ansems, Isadora Lopes Alves, et al.
Neurology|September 24, 2021
CSF Synaptic Biomarkers in the Preclinical Stage of Alzheimer Disease and Their Association With MRI and PET: A Cross-sectional StudyMarta Milà-Alomà, Ann Brinkmalm, Nicholas J Ashton, et al.
Elife|April 17, 2023
Biological brain age prediction using machine learning on structural neuroimaging data: Multi-cohort validation against biomarkers of Alzheimer's disease and neurodegeneration stratified by sexIrene Cumplido-Mayoral, Marina García-Prat, Grégory Operto, et al.
Alzheimer'S Research & Therapy|October 31, 2025
Sex differences in Alzheimer's disease CSF biomarkers and their association with Aβ pathology on PET in cognitively unimpaired individualsMarta Milà-Alomà, Carol Van Hulle, Anna Brugulat-Serrat, et al.
JAMA Neurology|October 18, 2021
Differences Between Plasma and Cerebrospinal Fluid Glial Fibrillary Acidic Protein Levels Across the Alzheimer Disease ContinuumAndréa L Benedet, Marta Milà-Alomà, Agathe Vrillon, et al.
Neuroimage. Clinical|November 21, 2025
Amyloid PET predicts atrophy in older adults without dementia: Results from the AMYPAD Prognostic & Natural History studyLeonard Pieperhoff, Luigi Lorenzini, Sophie Mastenbroek, et al.
Pageof 6

Showing results (41-50 of 59) with videos related to

Sort By:
Pageof 6
EJNMMI Research|March 1, 2023
APOE-ε4 modulates the association between regional amyloid deposition and cognitive performance in cognitively unimpaired middle-aged individualsAnna Brugulat-Serrat, Gonzalo Sánchez-Benavides, Raffaele Cacciaglia, et al.
Nature Medicine|September 13, 2022
Publisher Correction: Plasma p-tau231 and p-tau217 as state markers of amyloid-β pathology in preclinical Alzheimer's diseaseMarta Milà-Alomà, Nicholas J Ashton, Mahnaz Shekari, et al.
Nature Medicine|August 11, 2022
Plasma p-tau231 and p-tau217 as state markers of amyloid-β pathology in preclinical Alzheimer's diseaseMarta Milà-Alomà, Nicholas J Ashton, Mahnaz Shekari, et al.
EMBO Molecular Medicine|November 10, 2020
Novel tau biomarkers phosphorylated at T181, T217 or T231 rise in the initial stages of the preclinical Alzheimer's continuum when only subtle changes in Aβ pathology are detectedMarc Suárez-Calvet, Thomas K Karikari, Nicholas J Ashton, et al.
Brain Communications|July 5, 2022
Regional associations of white matter hyperintensities and early cortical amyloid pathologyLuigi Lorenzini, Loes T Ansems, Isadora Lopes Alves, et al.
Neurology|September 24, 2021
CSF Synaptic Biomarkers in the Preclinical Stage of Alzheimer Disease and Their Association With MRI and PET: A Cross-sectional StudyMarta Milà-Alomà, Ann Brinkmalm, Nicholas J Ashton, et al.
Elife|April 17, 2023
Biological brain age prediction using machine learning on structural neuroimaging data: Multi-cohort validation against biomarkers of Alzheimer's disease and neurodegeneration stratified by sexIrene Cumplido-Mayoral, Marina García-Prat, Grégory Operto, et al.
Alzheimer'S Research & Therapy|October 31, 2025
Sex differences in Alzheimer's disease CSF biomarkers and their association with Aβ pathology on PET in cognitively unimpaired individualsMarta Milà-Alomà, Carol Van Hulle, Anna Brugulat-Serrat, et al.
JAMA Neurology|October 18, 2021
Differences Between Plasma and Cerebrospinal Fluid Glial Fibrillary Acidic Protein Levels Across the Alzheimer Disease ContinuumAndréa L Benedet, Marta Milà-Alomà, Agathe Vrillon, et al.
Neuroimage. Clinical|November 21, 2025
Amyloid PET predicts atrophy in older adults without dementia: Results from the AMYPAD Prognostic & Natural History studyLeonard Pieperhoff, Luigi Lorenzini, Sophie Mastenbroek, et al.
Pageof 6